Ipsos Extends Cardiovascular Series

Ipsos Healthcare has extended its syndicated Cardiovascular Therapy Monitor Portfolio with the addition of a Monitor covering Stroke Prevention in Atrial Fibrillation (SPAF).

The Global Therapy Monitor range provides syndicated patient chart audit data for treatments across twenty plus disease areas including Metabolics, Oncology, Virology, Autoimmune and Cardiovascular, with data from 4000 physicians reporting on 200,000 patients in 35 markets worldwide.

The Cardiovascular range already includes Venous Thromboembolism (VTE), Pulmonary Arterial Hypertension (PAH) and Hypertension. The new SPAF Monitor tracks the treatment across the five biggest EU economies, the US, South Korea, Japan and Brazil and includes current drug shares, doctors' current and future prescribing intentions, and factors driving their decision-making.

Dr Sabina Heinz, Head of Ipsos Healthcare's Cardiovascular Therapy Monitor Portfolio, says the SPAF landscape is broadening rapidly with the introduction of Novel Oral Anticoagulants (NOACs), after decades when treatment consisted either of the drug Warfarin - burdensome for the patient - or of simple aspirin. She adds: @Against this backdrop, our SPAF monitor will answer critical questions such as, 'What split of drugs are doctors giving to their patients right now', and, more importantly, 'What do they expect to be doing in 12 months' time'?'

The group is online at www.ipsos.com .

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.

• Ipsos UK
• All news
• MrWeb info